National and Kapodistrian University of Athens
Επίδραση της λεβοσιμεντάνης στη νεφρική λειτουργία ασθενών με απορρυθμισμένη χρόνια καρδιακή ανεπάρκεια
Abstract
dc:descriptionBackground: The increased incidence of renal impairment and worsening renal function (WRF) in patients with acute heart failure (AHF) as well as, their correlation with adverse outcomes, raises the emerge for early diagnosis and management. The use of novel biomarkers, including cystatin C, which can estimate more accurately glomerular filtration rate (GFR) and are less influenced by confounding nonrenal factors, is crucial for these patients. Levosimendan, a calcium-sensitizing inotrope, has been correlated with reduction in serum creatinine, whereas its impact on cystatin C, compared with placebo or other inotropes, remains undefined.Aim: The objective of this study was to evaluate the effects of levosimendan on markers of kidney function in patients with acutely decompensated heart failure and renal impairment.Methods: The study included 96 patients hospitalized for acutely decompensated heart failure (ADHF) with symptoms of NYHA class III-IV, systolic dysfunction (ejection fraction ≤ 35%), and renal impairment [estimated glomerular filtration rate (eGFR) <60 ml/min] on admission. Half of these patients received levosimendan and the rest (age-, sex- and cardiac and renal severity-matched) patients received standard treatment (diuretics or/and other inotropes). WRF was defined as an increase in serum ceatinine ≥ 0.3 mg/dl from baseline.Results: Patients were on average 70±9 years old. Serum creatinine decreased but without any significant interaction with treatment (-0.13±0.25 έναντι -0.10±0.58, p=NS, respectively). Cystatin C decreased only in the levosimendan arm (-0.14±0.46 έναντι 0.06±0.51, F=2.985, p=0.088) and there was a trend towards a statistically significant interaction. WRF was less frequently observed with levosimendan administration (4.3% vs. 18.8%, p=0.03).Furthermore, in the overall population, in-hospital rise in cystatin C ≥ 0.4 mg/l was related with higher incidence of major adverse cardiac events (MACE) at 60 days (75% vs. 36% chi-square test p = 0.035; log-rank test p=0.05). Apart from this prognostic factor, BNP value at discharge ≥ 356 pg/ml was also an independent predictor of adverse outcomes (HR=4.457, 95% CI=1.292-15.379, p=0.018). Combining those two parameters (cystatin C change < or ≥ 0.4 mg/l and discharged BNP < or ≥ 356 pg/ml) stratified further the risk of events at 60 days (log-rank test p=0.016).Conclusions: In patients with ADHF and renal dysfunction on admission, levosimendan administration was related with improvement in renal biomarkers, compared to standard therapy. However, large-scale prospective studies are required to clarify the clinical significance of this observation and its impact on prognosis of heart failure patients. Interestingly, in this population in-hospital rise in cystatin C levels and BNP discharge levels had additive prognostic value at short-term.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2015
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Rafouli-Stergiou, Pinelopi
- Ραφούλη-Στεργίου, Πηνελόπη
Subjects
dc:subject × 10Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/35952